top of page


Series supported by Intellia Therapeutics

Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease

Laura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics

About Laura Sepp-Lorenzino

Safety considerations in therapeutic genome editing

Toni Cathomen, University of Freiburg

About Toni Cathomen

Repurposing of bacterial CRISPR-Cas immunity for genome editing

Virgis Siksnys, Vilnius University, Institute of Biotechnology

Video available to ESGCT members only

About Virgis Siksnys


bottom of page